Percutaneous Coronary Intervention with Procedural Unfractionated Heparin without Activated Clotting Time Guidance: A Unique Opportunity to Assess Thrombotic and Bleeding Events
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.Weight-adjusted unfractionated heparin (UFH) during percutaneous coronary intervention (PCI) without activated clotting time (ACT) monitoring showed low rates of major bleeding and intraprocedural thrombotic events (IPTE). This approach is safe and effective for patients undergoing PCI.
Area Of Science
- Cardiology
- Interventional Cardiology
- Pharmacology
Background
- The safety and efficacy of weight-adjusted unfractionated heparin (UFH) during percutaneous coronary intervention (PCI) without activated clotting time (ACT) monitoring remain underexplored.
- Understanding complication rates is crucial for optimizing anticoagulation strategies in PCI procedures.
Approach
- A retrospective review of 2,748 patients undergoing coronary angiography was conducted.
- 718 patients receiving weight-adjusted UFH without ACT monitoring during PCI were analyzed for major bleeding and intraprocedural thrombotic events (IPTE).
- Data on bleeding complications and IPTE were collected from medical records and angiogram reviews.
Key Points
- The study included 718 patients (mean age 65.4 years, 81.3% male).
- Overall, 7.8% of patients experienced either major bleeding or IPTE.
- Major bleeding occurred in 1.5% of patients, with femoral access associated with higher complication rates (6.6%) compared to radial access (0.2%).
- Common IPTE included slow/no reflow (1.5%) and coronary artery dissection with decreased flow (1.1%).
Conclusions
- Weight-adjusted UFH use during PCI without ACT monitoring is associated with low rates of major bleeding and IPTE.
- This anticoagulation strategy appears safe and effective in the context of PCI.
- Further research may support the adoption of this protocol in clinical practice.
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
Related Concept Videos
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
Hemostasis is a complex physiological process that prevents excessive bleeding when a blood vessel is injured. It's crucial for maintaining the integrity of the circulatory system, as it ensures that our blood remains fluid while still within the vascular network and yet clots to prevent blood loss upon vessel injury.
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...